



PRIVEQ INVESTMENT

Stockholm den 2009-11-05

Box 5295
SE-102 46 Stockholm
Besök/visit: Riddargatan 17
Tel: +46 8 459 67 60
Fax: +46 8 20 35 66
info@priveq.se
www.priveq.se

PRIVEQ INVESTMENT HELPS CREATE NEW SPECIALIST PHARMACEUTICALS COMPANY

Priveq has entered an agreement to divest its holding in pharmaceuticals company Swedish Orphan International to Biovitrum today, creating Swedish Orphan Biovitrum AB.

Swedish Orphan International has been highly successful in the period of over five years Priveq has been an active owner of the company. In this period, sales have grown from SEK 302 m to SEK 694 m, while operating earnings have increased from SEK 35 m to SEK 201 m.

When Priveq acquired the company in partnership with Investor Growth Capital and the company's CEO, an expansion strategy was prepared based on internationalization, an extended product range with a particular focus on a higher share of proprietary products, as well as preparing for the stock market. After over five years active ownership, the company has evolved from being a Nordic operation to a full-scale pan-European group through subsidiaries in Germany, France, the UK, Spain, Italy, the Czech Republic and Russia, capable of providing pharmaceuticals sales and distribution Europe wide. Two proprietary products, a raft of products with European market rights and straight licensed offerings have been added to the product portfolio. In this period, the company has been prepared for an initial public offering, while considering opportunities for a trade sale. We are now able to conclude that the merger with Biovitrum is the best possible option for the company's future, while the deal per se is a combination of our exit options—a trade sale with the company securing stock market status as the new merged entity, Swedish Orphan Biovitrum.

In the transaction, the company's value is SEK 3.5 bn on a debt-free basis. The investment in Swedish Orphan International has been the most successful since our incorporation in 1983 measured as a return on invested capital multiple.

Editor's Notes—Priveq Investment

Priveq Investment is a private equity firm with AUM of over SEK 2 bn in two funds. Its business concept is to create value through long-term investment in, and active ownership of, unlisted growth companies. Investors in Priveq's funds include Sweden's Fourth National Pension Insurance Fund, life insurer Handelsbanken Liv, the Swedish Co-operative Society's investment arm KF Invest, life insurer Skandia Liv, Sweden's Third National Pension Insurance Fund and Scandinavian telco Telia's pension fund. Since incorporation in 1983, Priveq Investment has made over 100 investments and participated in 24 of its portfolio companies' IPOs. For more information, go to: www.priveq.se.